Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (NCT02366884) (2022)

Government Record · Dr. Frank Arguello Cancer Clinic; Instituto de Ciencia y Medicina Genomica, Torreon, Coahuila, Mexico · April 6, 2022

Dr. Frank Arguello Cancer Clinic, 2022-04-06: Mexican phase II registration of an 'atavistic chemotherapy' protocol in which ivermectin is one of several anti-protozoal agents combined with antibacterials and antifungals in patients with neoplasms; status unknown, no results.

Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole

Dr. Frank Arguello Cancer Clinic, 2022-04-06: Mexican phase II registration of an 'atavistic chemotherapy' protocol in which ivermectin is one of several anti-protozoal agents combined with antibacterials and antifungals in patients with neoplasms; status unknown, no results. C1 record field. Country Mexico; phase 2; estimated enrollment 250; start 2011-07-26; status UNKNOWN (last update 2022-04-06); no results. Ivermectin appears only as one agent inside multi-drug arms, and the record gives no ivermectin dose. Registered, no results. Registry entry; no results posted. Study type: regulatory record.